Plozasiran Injection

DRUG4 trials

Sponsors

Arrowhead Pharmaceuticals

Conditions

HypertriglyceridemiaSevere Hypertriglyceridemia

Phase 3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Active, not recruitingNCT06347003

Arrowhead PharmaceuticalsSevere Hypertriglyceridemia

Start: 2024-07-22End: 2026-09-01Updated: 2026-07-15

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Active, not recruitingNCT06347133

Arrowhead PharmaceuticalsHypertriglyceridemia

Start: 2024-05-21End: 2026-09-01Updated: 2026-06-26

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Active, not recruitingNCT06347016

Arrowhead PharmaceuticalsSevere Hypertriglyceridemia

Start: 2024-07-23End: 2026-09-01Updated: 2026-08-06

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

RecruitingNCT06822790

Arrowhead PharmaceuticalsHypertriglyceridemia

Start: 2025-04-09End: 2028-07-01Target: 869Updated: 2026-08-12